Nextage Therapeutics (XTAE:NXTG) Gross-Profit-to-Asset % : 42.73% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nextage Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was ₪0.37 Mil. Nextage Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was ₪0.87 Mil. Therefore, Nextage Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 42.73%.

Nextage Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Nextage Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Gross-Profit-to-Asset % Chart

Nextage Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.53

0.38

17.26

Nextage Therapeutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									-2.57	-	-	7.23	42.73

Competitive Comparison of Nextage Therapeutics's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Gross-Profit-to-Asset % falls into.

Nextage Therapeutics Gross-Profit-to-Asset % Calculation

Nextage Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0.225	/	( (1.512	+	1.095)	/ 2 )
	=	0.225	/	1.3035
	=	17.26 %

Nextage Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.372	/	( (0.646	+	1.095)	/ 2 )
	=	0.372	/	0.8705
	=	42.73 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Nextage Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextage Therapeutics (XTAE:NXTG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581

Website

http://www.m-medic.com

Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines

From GuruFocus

First Trust Global Portfolios Limited Announces Name Changes for Certain Sub-Funds of First Trust Global Funds plc

By Business Wire Business Wire • 01-29-2021